Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2003-05-02
2009-12-22
Lucas, Zachariah (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S185100, C424S186100, C424S192100, C424S204100, C424S212100, C435S235100
Reexamination Certificate
active
07635752
ABSTRACT:
Control apparatus forcefully stops inverter and inverter when DC/DC converter is anomalously stopped. Additionally, when one of inverters is anomalously stopped while DC/DC converter is normal, control apparatus forcefully stops the other inverter. Then, when a recovery condition is satisfied after the other inverter is forcefully stopped, control apparatus recovers the other inverter.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: WO 01/20989 (2001-03-01), None
patent: WO 02/23994 (2002-03-01), None
Plemper et al., “Characterization of a region of the measles virus hemagglutinin sufficient for its dimerization,” Journal of Virology, vol. 74 No. 14, pp. 6485-6493 (Jul. 2000).
Vongpunsawad et al., “Selectively Receptor-Blind Measles Viruses: Identification of Residues Necessary for SLAM- or CD46- Induced Fusion and Their Localization on a New Hemagglutinin Structural Model,” Journal of Virology, vol. 78 No. 1, pp. 302-313 (Jan. 2004).
Outlaw et al., “Sequence variation within an outbreak of measles virus in the Coventry area during spring/summer 1993,” Virus Research, vol. 39 No. 1, pp. 3-11 (Nov. 1995).
Plemper et al., “Characterization of a region of the measles virus hemagglutinin sufficient for its dimerization,” Journal of Virology, vol. 74 No. 14, pp. 6485-6493 (Jul. 2000).
Vongpunsawad et al., “Selectively Receptor-Blind Measles Viruses: Identification of Residues Necessary for SLAM- or CD46- Induced Fusion and Their Localization on a New Hemagglutinin Structural Model,” Journal of Virology, vol. 78 No. 1, pp. 302-313 (Jan. 2004).
Masse et al., “Measles Virus (MV) Hemagglutinin: Evidence that Attachment Sites for MV Receptors SLAM and CD46 Overlap on the Globular Head,” Journal of Virology, vol. 78 No. 17, pp. 9051-9063 (Sep. 2004).
Schrag et al., “Spontaneous mutation rate of measles virus: direct estimation based on mutations conferring monoclonal antibody resistance,” Journal of Virology, vol. 73 No. 1, pp. 51-54 (Jan. 1999).
GenPept AAA56639, hemagglutinin, Dec. 1994.
GenBank Accession No. AC027082.3 dated Aug. 24, 2002, 58 pages.
GenBank Accession No. AL355996.3 dated Jul. 10, 2001, 52 pages.
Bartz et al., “Mapping Amino Acids of the Measles Virus Hemagglutinin Responsible for Receptor (CD46) Downregulation,”Virology, 1996, 224:334-337′.
Bateman et al., “Fusogenic Membrane Glycoproteins As a Novel Class of Genes for the Local and Immune-mediated Control of Tumor Growth,”Cancer Research, 2000, 60:1492-1497.
Borrow and Oldstone, “Measles Virus-Mononuclear Cell Interactions,”Curr. Top. Microbiol. Immunol., 1995, 191:85-100.
Buchholz et al., “Mapping of the Primary Binding Site of Measles Virus to Its Receptor CD46,”J. Biol. Chem., 1997, 272(35):22072-22079.
Buchholz et al., “Cell Entry by Measles Virus: Long Hybrid Receptors Uncouple Binding from Membrane Fusion,”J. Virol., 1996, 70:3716-3723.
Cathomen et al., “A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain,”EMBO J., 1998, 17:3899-3908.
Chester et al., “Phage libraries for generation of clinically useful antibodies,”Lancet, 1994, 343(8895):455-456.
Christiansen et al., “A CD46CD[55-46] chimeric receptor, eight short consensus repeats long, acts as an inhibitor of both CD46 (MCP)- and CD150 (SLAM)-mediated cell—cell fusion induced by CD46-using measles virus,”J. Gen. Virol., 2002, 83:1147-1155.
Clements and Cutts, “The Epidemiology of Measles: Thirty Years of Vaccination,”Measles Virus, pp. 13-33, ter Meulen and Billeter (eds.), Springer-Verlag, Berlin, 1995.
Cocks et al., “A novel receptor involved in T-cell activation,”Nature, 1995, 376:260-263.
Devaux et al., “CD46 Short Consensus Repeats III and IV Enhance Measles Virus Binding but Impair Soluble Hemagglutinin Binding,”J. Virol., 1997, 71(5):4157-4160.
Duclos and Ward,“Measles Vaccines—A Review of Adverse Events,”Drug Safety, 1998, 19(6):435-454.
Federspiel and Hughes, “Retroviral Gene Delivery,”Methods in Cell Biology, 1998, 52:179-214.
Galanis et al., “Use of Viral Fusogenic Membrane Glycoproteins as Novel Therapeutic Transgenes in Gliomas,”Human Gene Therapy, 2001, 12:811-821.
Griffin and Bellini, “Measles Virus,”Fields Virology, 1996; pp. 1267-1312, Fields et al. (eds.), Lippincott—Raven Publishers, New York.
Grote et al., “Live attenuated measles virus induce regression of human lymphoma xenografts in immunodeficient mice,”Blood, 2001, 97(12):3746-3754.
Hammond et al., “Single-Chain Antibody Displayed on a Recombinant Measles Virus Confers Entry through the Tumor-Associated Carcinoembryonic Antigen,”J. Virol., 2001, 75(5):2087-2096.
Hourcade et al., “Analysis of the Human Regulators of Complement Activation (RCA) Gene Cluster with Yeast Artificial Chromosomes (YACs),”Genomics, 1992, 12:289-300.
Hsu et al., “A Single Amino Acid Change in the Hemagglutinin Protein of Measles Virus Determines Its Ability to Bind CD46 and Reveals Another Receptor on Marmoset B Cells,”J. Virol., 1998, 72(4):2905-2916.
Hsu et al., “Use of Site-Specific Mutagenesis and Monoclonal Antibodies to Map Regions of CD46 That Interact with Measles Virus H Protein,”Virology, 1999, 258:314-326.
Hu et al., “Characterization of a region involved in binding of measles virus H protein and its receptor SLAM (CD 150),”Biochem. Biophys. Res. Commun., 2004, 316:698-704.
Lecouturier et al., “Identification of Two Amino Acids in the Hemagglutinin Glycoprotein of Measles Virus (MV) That Govern Hemadsorption, HeLa Cell Fusion, and CD46 Downregulation: Phenotypic Markers That Differentiate Vaccine and Wild-Type MV Strains,”J. Virol., 1996, 70 (7):4200-4204.
Linardakis et al., “Regulated Expression of Fusogenic Membrane Glycoproteins,”Gene Therapy, 1999, 6(1):S4, abstract 13.
Martin et al., “Studies of the binding properties of influenza hemagglutinin receptor-site mutants,”Virology, 1998, 241(1):101-111.
Mori et al., “A novel amino acid substitution at the receptor-binding site on the hemagglutinin of H3N2 influenza A viruses isolated from 6 cases with acute encephalopathy during the 1997-1998 season in Tokyo,”Arch. Virol., 1999, 144(1):147-155.
Mrkic et al., “Measles Virus Spread and Pathogenesis in Genetically Modified Mice,”J. Virol., 1998, 72(9):7420-7427.
Nies and Spielberg, “Principles of Therapeutics,”The Pharmacological Basis of Therapeutics, 1996, Chapter 3, pp. 43-62.
Nussbaum et al., “Functional and Structural Interactions between Measles Virus Hemagglutinin and CD46,”J. Virol., 1995, 69(6):3341-3349.
Patterson et al., “Structural and Functional Studies of the Measles Virus Hemagglutinin: Identification of a Novel Site Required for CD46 Interaction,”Virology, 1999, 256:142-151.
Peng et al., “Systemic therapy of myeloma xenografts by an attenuated measles virus,”Blood, 2001, 98(7):2002-2007.
Peng et al., “Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker,”Blood, 2003, 101(7):2557-2562.
Radecke et al., “Rescue of measles viruses from cloned DNA,”EMBO J., 1995, 14(23):5773-5784.
Schneider et al., “Efficiency of Measles Virus Entry and Dissemination through Different Receptors,”J. Virol., 2002, 76(15):7460-7467.
Schneider et al., “Recombinant Measles Viruses Efficiently Entering Cells through Targeted Receptors,”J. Virol., 2000, 74(21):9928-9936.
Steinhauer et al., “Studies using double mutants of the conformational transitions in influenza hemagglutinin required for its membrane fusion activity,”Proc. Natl. Acad. Sci. USA, 1996, 93(23):12783-12788.
Sutter et a
Cattaneo Roberto
Nakamura Takafumi
Russell Stephen J.
Vongpunsawad Sompong
Fish & Richardson P.C.
Lucas Zachariah
Mayo Foundation for Medical Education and Research
LandOfFree
Ablated SLAM-Dependent Entry does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ablated SLAM-Dependent Entry, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ablated SLAM-Dependent Entry will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4109976